Australia is closely watching the arrival of retatrutide, a cutting-edge dual GIP and GLP-1 receptor agonist , representing a potential advance in obesity treatment . Early research findings have demonstrated https://giant-hybrid-bike451860.mysticwiki.com/2675348/new_treatment_in_australia_a_promising_solution_for_obesity_management